Aurobindo Pharma gets USFDA nod for generic migraine drug

By: |
New Delhi | May 13, 2016 3:17 PM

Aurobindo Pharma has received approval from the US health regulator to sell generic Zolmitriptan tablets, a drug used to treat migraine, in the American market.

Aurobindo PharmaAurobindo Pharma has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Zolmitriptan Tablets in strengths of 2.5 mg and 5 mg. (Photo: Reuters)

Aurobindo Pharma has received approval from the US health regulator to sell generic Zolmitriptan tablets, a drug used to treat migraine, in the American market.

The company has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Zolmitriptan Tablets in strengths of 2.5 mg and 5 mg, Aurobindo Pharma said in a regulatory filing.

“This product is expected to be launched in second quarter of FY16-17,” it added.

The company’s product is the generic equivalent of IPR Pharmaceuticals’ Zomig, which is used in the treatment of migraine in adults.

“The approved product has an estimated market size of $46.7 million for the 12 months ending March 2016 according to IMS,” Aurobindo Pharma said.

With this approval, the company has now a total of 260 abbreviated new drug application (ANDA) approvals from the USFDA.

Aurobindo shares were trading at Rs 789.45 on BSE, down 1.48 per cent from the previous close.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, Check out latest IPO News, Best Performing IPOs, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1Moody’s affirms Ba2 rating of GMR Hyderabad International Airport
2Dish TV gets requisition from Yes Bank to call EGM
3PFC, REC disburse Rs 85,000 crore to discoms under Atmanirbhar Bharat package